Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122)
China
· Delayed Price · Currency is CNY 32.09
-2.64 (-7.60%)
Oct 11, 2024, 11:13 AM CST
Chongqing Zhifei Biological Products Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 6,044 | 8,070 | 7,539 | 10,209 | 3,301 | 2,366 | Upgrade
|
| Depreciation & Amortization | 353.04 | 320.73 | 314.94 | 375.85 | 120.93 | 88.51 | Upgrade
|
| Other Amortization | 19 | 17.65 | 15.89 | 13.01 | 10.5 | 8.05 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.72 | -41.37 | -0.01 | -0.04 | -0.02 | -0 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.24 | 0.13 | 0.09 | 1.68 | 0.55 | 0.73 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | 20.03 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 435.17 | 352.59 | 420.87 | 190.74 | 82.93 | 68.11 | Upgrade
|
| Other Operating Activities | 350.31 | 394.49 | 166.06 | 134.48 | 183.92 | 93.38 | Upgrade
|
| Change in Accounts Receivable | -20.32 | -6,756 | -8,056 | -6,546 | -2,249 | -2,531 | Upgrade
|
| Change in Inventory | -4,639 | -1,313 | -765.61 | -3,982 | -974.81 | -729.83 | Upgrade
|
| Change in Accounts Payable | 4,399 | 8,338 | 2,413 | 8,064 | 3,065 | 2,005 | Upgrade
|
| Operating Cash Flow | 6,512 | 8,996 | 1,989 | 8,508 | 3,497 | 1,367 | Upgrade
|
| Operating Cash Flow Growth | 17.41% | 352.30% | -76.62% | 143.30% | 155.79% | 133.44% | Upgrade
|
| Capital Expenditures | -1,012 | -1,134 | -1,453 | -1,932 | -826.98 | -572.93 | Upgrade
|
| Sale of Property, Plant & Equipment | 171.96 | 168.07 | 0.65 | 0.32 | 0.1 | 0.2 | Upgrade
|
| Investment in Securities | -10.5 | -10.5 | -45.5 | -69 | -70 | -50 | Upgrade
|
| Other Investing Activities | 12.42 | - | - | -18.55 | - | - | Upgrade
|
| Investing Cash Flow | -837.87 | -976.6 | -1,498 | -2,019 | -896.88 | -622.73 | Upgrade
|
| Short-Term Debt Issued | - | 5.54 | 39.08 | 94.63 | 411.63 | 3,310 | Upgrade
|
| Long-Term Debt Issued | - | 6,342 | 5,477 | 2,569 | 6,653 | - | Upgrade
|
| Total Debt Issued | 9,118 | 6,348 | 5,517 | 2,663 | 7,065 | 3,310 | Upgrade
|
| Short-Term Debt Repaid | - | -0.39 | -18.64 | -75.01 | -216.26 | -2,818 | Upgrade
|
| Long-Term Debt Repaid | - | -9,739 | -6,643 | -5,312 | -8,032 | - | Upgrade
|
| Total Debt Repaid | -12,156 | -9,739 | -6,661 | -5,387 | -8,249 | -2,818 | Upgrade
|
| Net Debt Issued (Repaid) | -3,038 | -3,391 | -1,145 | -2,723 | -1,184 | 492.31 | Upgrade
|
| Common Dividends Paid | -104.42 | -889.29 | -1,015 | -861.96 | -928.7 | -870.68 | Upgrade
|
| Other Financing Activities | -14.47 | -13.08 | -12.82 | -4.76 | -0.72 | -14.43 | Upgrade
|
| Financing Cash Flow | -3,457 | -4,294 | -2,173 | -3,590 | -2,114 | -392.8 | Upgrade
|
| Foreign Exchange Rate Adjustments | -1.41 | -2.3 | 17.56 | -9.66 | -4.93 | 0.85 | Upgrade
|
| Net Cash Flow | 2,216 | 3,724 | -1,664 | 2,889 | 481.29 | 352.31 | Upgrade
|
| Free Cash Flow | 5,500 | 7,862 | 535.93 | 6,575 | 2,670 | 794.06 | Upgrade
|
| Free Cash Flow Growth | 26.25% | 1367.02% | -91.85% | 146.30% | 236.21% | 650.77% | Upgrade
|
| Free Cash Flow Margin | 11.77% | 14.86% | 1.40% | 21.45% | 17.57% | 7.50% | Upgrade
|
| Free Cash Flow Per Share | 2.29 | 3.28 | 0.22 | 2.74 | 1.11 | 0.33 | Upgrade
|
| Cash Income Tax Paid | 3,334 | 3,310 | 3,274 | 1,955 | 875.44 | 732.88 | Upgrade
|
| Levered Free Cash Flow | - | 1,494 | -3,931 | 2,887 | -96.68 | -1,129 | Upgrade
|
| Unlevered Free Cash Flow | - | 1,545 | -3,898 | 2,922 | -17.22 | -1,081 | Upgrade
|
| Change in Net Working Capital | - | 3,413 | 8,212 | 2,987 | 1,829 | 2,396 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.